|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's Range||22.30 - 24.45|
|52 Week Range||6.56 - 24.45|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||49.40|
NEW YORK, May 24, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Opexa ...
Although overlooked by the investors, Opexa Therapeutics (ACER) looks well-positioned for a solid gain, supported by a favorable Zacks rank and positive estimate revisions.
Acer continues progression from development to potential commercialization of EDSIVO™. Company appoints Chief Legal Officer and 3 new VPs of Clinical Operations, Program and Alliance Management, and Market ...